Page 210 - COMMUNITY PHARMACY PRACTICE

02/04/2024

424

SECOND GENERATION NSAIDS:

¨ Rofecoxib was approved by FDA on May 20,1990 but
on September 30,2004 rofecoxib was ………… from
the market because of concerns about increased risk of
heart attack associated with long term use , high doses.

¨ If a cox-2 inhibitor is taken, one should not use a
traditional NSAIDs concomitantly.

Celecoxib(Celebrex, Arythrex)
vFDA approved this drug for clinical use.

424

425

Contraindications

•DON’T DISPENSE CELECOXIB IN CASE OF HREAT
PROBLEM
Celebrex has been associated with an increased risk of
serious adverse cardiovascular (CV) events in a long-term
placebo controlled trial.
•Celecoxib contains a sulfonamide moiety and may cause
…….in those allergic to other sulfonamide-containing drugs or
other NSAID

425

212